Preliminary studies by researchers at the Mayo Clinic, they are associated with the high level of the HtrA1 protein and pre-eclampsia. These findings have been made public at the annual meeting of the Society for Maternal-Fetal Medicine in Miami being held these days.
This finding could lead to the development of a blood test that can follow HtrA1 levels and identify women at risk of pre-eclampsia, since at present there is no test that can predict it.
Research evaluated the levels of this protein in specific cells from placentas from women with normal blood pressure, mild preeclampsia and severe pre-eclampsia, discovering the highest levels of the HtrA1 protein in placentas from women with pre-eclampsia Q3 serious.
The team of Dr. Brian Brost, said that high levels of this protein in women with severe pre-eclampsia, could cause a malfunction during the second stage of growth of the key placental cells called cytotrophoblasts, based on their migration to the uterus and the placenta.
The development of a blood test to detect levels of HtrA1, could be an early warning system for preventing pre-eclampsia.